Doluvir 50 Mg Tablets

Description

What Is Doluvir 50mg Tablet?

Doluvir 50mg Tablet is an oral prescription antiretroviral medication manufactured by Hetero Healthcare Ltd. Each film-coated tablet contains Dolutegravir (as dolutegravir sodium) 50 mg.

Doluvir belongs to the pharmacological class of integrase strand transfer inhibitors (INSTIs), widely considered a preferred anchor class in modern HIV-1 care. It is prescribed under specialist medical supervision (by an infectious disease physician, HIV specialist, or clinical pharmacologist) as part of combination antiretroviral therapy (cART) to treat Human Immunodeficiency Virus Type 1 (HIV-1) in adult and pediatric patients.

Dolutegravir is globally recognized for its high potency, rapid viral load suppression, favorable tolerability profile, and remarkably high genetic barrier to resistance compared to first-generation integrase inhibitors.

Quick Product Fact Sheet

• Brand Name: Doluvir 50mg Tablet
• Active Ingredient: Dolutegravir sodium (equivalent to 50 mg dolutegravir)
• Manufacturer: Hetero Healthcare Ltd.
• Therapeutic Class: Antiretroviral agent
• Pharmacological Class: Integrase Strand Transfer Inhibitor (INSTI)
• Dosage Form: Film-coated oral tablet
• Standard Adult Dose: One 50mg tablet taken orally once daily (or twice daily in specific scenarios)
• Dietary Rule: Can be taken with or without food
• Packaging: Bottle of 30 tablets with moisture-absorbing desiccant

How Doluvir 50mg Works

To establish permanent infection and multiply inside human immune cells, HIV-1 must insert its viral genetic blueprint into the host cell’s DNA. This integration step is carried out by a specific viral enzyme known as HIV integrase.

The Mechanism of Action Explained:

• Binding the Catalytic Core: Once inside the infected CD4+ T-cell, dolutegravir targets and binds to the active site of the HIV integrase enzyme.
• Magnesium Ion Chelation: Dolutegravir chelates two essential divalent magnesium cations (Mg2+) within the catalytic pocket. These metal ions are necessary for the enzyme’s catalytic function.
• Halting Strand Transfer: By deactivating these metal ions, dolutegravir blocks the crucial “strand transfer” step, preventing the ends of the viral DNA from joining into human genomic DNA.
• Aborting Viral Assembly: Because unintegrated viral DNA cannot undergo transcription and protein synthesis, the viral replication process stops entirely, and the unintegrated viral material is naturally degraded by cellular enzymes.
• Slow Dissociation Rate: Dolutegravir detaches from the integrase-DNA complex very slowly (prolonged dissociation half-life of roughly 71 hours). This extended binding time makes it difficult for the virus to mutate around the drug, giving it a high genetic barrier to resistance.

Approved Clinical Indications

Doluvir 50mg Tablet is indicated for adult and pediatric patients (weighing 20 kg or more) in the following settings:

• Treatment-Naive HIV-1 Infection: Prescribed as a primary anchor agent in combination with two nucleoside reverse transcriptase inhibitors (such as tenofovir disoproxil fumarate/emtricitabine, tenofovir alafenamide/emtricitabine, or abacavir/lamivudine).
• Treatment-Experienced, INSTI-Naive Patients: Indicated for patients whose prior non-integrase regimens (such as NNRTI- or PI-based therapies) have failed or require optimization due to tolerability issues.
• INSTI-Resistant HIV-1 Infection: Approved for individuals whose viral strains have documented or clinically suspected resistance to first-generation integrase inhibitors (raltegravir or elvitegravir). In this scenario, dolutegravir is administered on an intensified twice-daily schedule.
• Post-Exposure Prophylaxis (PEP): Frequently utilized as the anchor drug in 28-day emergency occupational or non-occupational post-exposure prophylaxis regimens.

Important Note: Doluvir does not cure HIV-1 infection. Consistent daily adherence is required to maintain undetectable viral levels, preserve immune health, and prevent sexual transmission (Undetectable = Untransmittable, or U=U).

Standard Dosage and Administration Guidelines

Doluvir must be taken strictly as prescribed by your infectious disease physician.

Standard Dosage Framework

• Treatment-Naive or INSTI-Naive Adults and Adolescents (weighing 20 kg or more): One 50mg tablet once daily (50 mg/day).
• Patients with Documented or Suspected INSTI Resistance: One 50mg tablet twice daily spaced 12 hours apart (100 mg/day).
• Co-Administration with Specific Inducers: (e.g., Efavirenz, Nevirapine, Rifampin, Tipranavir/Ritonavir) One 50mg tablet twice daily to compensate for accelerated drug clearance (100 mg/day).

Food and Dietary Guidance

Doluvir can be taken with or without food. Taking it with meals can help lessen mild, initial stomach sensitivity. However, when taken by patients with documented INSTI resistance, taking Doluvir with a meal is often advised to slightly increase drug exposure.

Administration Checkpoints

• Swallow Whole: Swallow the tablet whole with a glass of water. Do not chew, crush, split, or dissolve the tablet.
• Daily Consistency: Take your dose at the exact same time every day to ensure steady drug levels in your bloodstream.
• Missed Dose Protocol: If taking once daily: If you miss a dose, take it as soon as you remember, unless it is within 4 hours of your next scheduled dose. If less than 4 hours remain, skip the missed dose and resume your regular schedule. Never take a double dose to make up for a missed tablet.

The Critical Separation Rule: Mineral Supplements & Antacids

Dolutegravir binds strongly to polyvalent metal cations (minerals like magnesium, aluminum, iron, and calcium). When taken together, the minerals bind to dolutegravir in the stomach, forming an insoluble complex that passes out of the body without being absorbed, leading to sub-therapeutic blood levels and treatment failure.

• Antacids containing Aluminum or Magnesium: Take Doluvir at least 2 hours before or 6 hours after taking the antacid.
• Calcium or Iron Supplements: If taken with food, Doluvir and calcium/iron supplements can be taken at the same time. If taken on an empty stomach, maintain the 2-hour before or 6-hour after separation window.

Potential Side Effects & Clinical Management

Doluvir is generally well tolerated, with a lower rate of treatment discontinuation compared to older antiretroviral classes.

Common Adverse Reactions

• Nervous System: Headache, dizziness, fatigue, or difficulty sleeping (insomnia).
• Digestive Symptoms: Mild nausea, diarrhea, abdominal discomfort, or flatulence.
• Weight Gain: Modern INSTI-based regimens, including dolutegravir, have been linked with moderate weight gain during the first 1 to 2 years of therapy, particularly when paired with tenofovir alafenamide (TAF).

Serious Warnings (Seek Immediate Medical Care)

• Severe Hypersensitivity Reactions: Characterized by skin rash accompanied by fever, severe fatigue, muscle or joint aches, blisters, oral lesions, facial swelling, or breathing difficulty. If a hypersensitivity reaction is suspected, stop Doluvir immediately and seek emergency care. Never restart dolutegravir after an allergic reaction.
• Hepatotoxicity (Liver Stress): Elevations in liver enzymes (ALT, AST) can occur, especially in individuals with underlying Hepatitis B or Hepatitis C co-infection. Watch for yellowing of the skin or eyes (jaundice), dark brown urine, or upper right-sided abdominal pain.
• Immune Reconstitution Inflammatory Syndrome (IRIS): As the immune system regains strength, it can produce an exaggerated inflammatory response against pre-existing, dormant infections (such as tuberculosis, cytomegalovirus, or fungal pneumonia).
• Neuropsychiatric Effects: Although rare, severe mood changes, worsening depression, anxiety, or suicidal thoughts have been reported, primarily in individuals with a pre-existing psychiatric history.

Precautions & Clinical Safety Monitoring

• HIV-1 Viral Load & CD4 Count: Baseline, at 4 to 8 weeks, then every 3 to 6 months to evaluate virologic suppression and confirm immune recovery.
• Liver Function Tests (ALT, AST, Bilirubin): Baseline, then periodic checks to screen for drug-induced liver injury, particularly in HBV/HCV co-infections.
• Kidney Function (eGFR & Serum Creatinine): Baseline and periodic. Note: Dolutegravir causes a small, benign increase in serum creatinine (~0.1 to 0.15 mg/dL) by inhibiting renal tubular secretion (OCT2 transporter) without actually reducing true glomerular filtration rate.
• Hepatitis B & C Serology: Baseline prior to initiating therapy to identify co-infections requiring concurrent HBV therapy.
• Weight and Metabolic Parameters: Baseline, then at routine clinical visits to track changes in body weight, fasting blood glucose, and lipid profiles.

Drug Interactions & Substance Warnings

• Dofetilide (Cardiac Antiarrhythmic): Co-administration with dofetilide is strictly contraindicated. Dolutegravir increases dofetilide blood levels by inhibiting OCT2 clearance, which can lead to life-threatening ventricular arrhythmias.
• Metformin (Diabetes Medication): Dolutegravir increases blood levels of metformin by blocking its kidney elimination. When initiating Doluvir, clinicians typically limit the total daily dose of metformin to a maximum of 1,000 mg to prevent lactic acidosis and hypoglycemia.
• Enzyme Inducers (Rifampin, Carbamazepine, Phenytoin, St. John’s Wort): These accelerate the metabolic clearance of dolutegravir via UGT1A1 and CYP3A4 pathways. When taken with rifampin, the Doluvir dose must be increased to 50 mg twice daily.
• Other Integrase Inhibitors: Do not combine Doluvir with other INSTIs (such as raltegravir, elvitegravir, or bictegravir).

Special Population Guidance

• Pregnancy: Extensively evaluated in global studies (including the Tsepamo study). Current WHO and DHHS guidelines endorse dolutegravir as a preferred first-line option across all trimesters of pregnancy, concluding that the benefits of rapid, durable viral suppression far outweigh any small initial concerns regarding neural tube defects.
• Breastfeeding: In settings where clean water and commercial infant formulas are accessible, mothers living with HIV are advised to avoid breastfeeding to eliminate transmission risks. In low-resource settings, exclusive breastfeeding under continuous suppressive antiretroviral therapy is supported by WHO guidelines.
• Renal Impairment: No dosage adjustment is needed for patients with mild, moderate, or severe kidney impairment, or those on hemodialysis, provided there is no documented INSTI resistance. (Patients with INSTI resistance and severe renal impairment require individualized specialist assessment).
• Hepatic Impairment: Safe in mild to moderate liver disease (Child-Pugh Class A or B). Not recommended for individuals with severe hepatic impairment (Child-Pugh Class C) due to limited safety data.
• Pediatric Use: Approved for pediatric patients weighing at least 20 kg using the adult 50 mg film-coated tablet. Lower-weight children require weight-adjusted dispersible tablet formulations.

Storage and Handling Protocols

• Store tablets at room temperature between 20°C and 25°C (68°F to 77°F). Brief excursions between 15°C and 30°C (59°F to 86°F) are acceptable.
• Keep tablets in their original packaging, tightly closed, in a dry place protected from excessive heat and direct moisture.
• Keep the desiccant canister inside the bottle until all tablets are consumed.
• Keep strictly out of reach of children and household pets.

Frequently Asked Questions (FAQs)

Q1: Can Doluvir 50mg be taken alone without other HIV medicines?
No. Doluvir 50mg contains only dolutegravir and cannot be used by itself to treat HIV. It is an anchor medication that must always be combined with other anti-HIV medicines (such as two NRTIs) or prescribed as part of an approved complete two-drug regimen (like dolutegravir plus lamivudine) under direct physician guidance.

Q2: Can I take my daily multivitamin or antacid at the same time as Doluvir?
No. Antacids and supplements containing calcium, iron, magnesium, or aluminum bind to dolutegravir in your stomach and stop your body from absorbing it. Take Doluvir at least 2 hours before or 6 hours after taking these mineral supplements.

Q3: Why did my blood creatinine level rise slightly after starting Doluvir?
Dolutegravir naturally blocks a protein in your kidneys (OCT2) that transports creatinine into the urine. This causes a small, predictable rise in blood creatinine (usually within the first 4 weeks) that does not reflect actual damage to your kidneys or a decline in your true kidney filtration rate.

Q4: Does Doluvir cure HIV permanently?
No. Doluvir does not eliminate dormant HIV from viral reservoirs in the body, meaning it is not a cure. However, taking it consistently every day keeps the virus undetectable in your bloodstream, protects your immune system, and ensures that the virus cannot be transmitted to sexual partners.

Medical Disclaimer: This clinical guide is strictly for educational, informational, and professional onboarding purposes and must not replace individualized medical advice, clinical diagnosis, or professional treatment. Always consult a qualified infectious disease specialist, clinical pharmacologist, or healthcare provider before initiating, modifying, or discontinuing any antiretroviral therapy.

References

• U.S. Food and Drug Administration (FDA): Tivicay (dolutegravir) Tablets Full Prescribing Information. View Source
• National Center for Biotechnology Information (NCBI): StatPearls Review: Dolutegravir Pharmacology, Mechanism of Action, and Clinical Use. View Source
• World Health Organization (WHO): Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery & Monitoring. View Source
• Clinical Info HIV.gov (U.S. Department of Health and Human Services): Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. View Source
• MedlinePlus (U.S. National Library of Medicine): Dolutegravir Monograph & Patient Instructions. View Source